(8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin-1-yl-phenyl)-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin-1-yl-phenyl)-amine
• 英文别名: 2-Aminoquinazoline 7；7-methoxy-8-propan-2-yl-N-(4-pyrrolidin-1-ylphenyl)quinazolin-2-amine
• 化学式: C₂₂H₂₆N₄O
• 分子量: 362.475
• InChiKey: AWFQXBDHAKLADX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  50.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  8-Isopropyl-7-methoxy-quinazolin-2-ylamine 在 tetrafluoroboric acid 、 sodium nitrite 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 生成 (8-Isopropyl-7-methoxy-quinazolin-2-yl)-(4-pyrrolidin-1-yl-phenyl)-amine
  参考文献：
  名称：

  细胞周期蛋白依赖性激酶的2-氨基喹唑啉抑制剂。

  摘要：

  抑制细胞周期蛋白依赖性激酶4（Cdk4）会导致细胞周期停滞，并恢复大多数肿瘤细胞中不存在的检查点。选择性抑制Cdk4的化合物可靶向治疗癌症。与紧密相关的丝氨酸-苏氨酸激酶相比，证明2-氨基喹唑啉的适当取代对Cdk4产生高水平的选择性。

  DOI：

  10.1016/j.bmcl.2005.05.131

文献信息

• QUINAZOLINES AND THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASE ENZYMES
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1235815A1

  公开（公告）日：2002-09-04
• US6982260B1
  申请人：——

  公开号：US6982260B1

  公开（公告）日：2006-01-03
• [EN] QUINAZOLINES AND THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASE ENZYMES<br/>[FR] QUINAZOLINES ET LEUR UTILISATION DANS L'INHIBITION DES ENZYMES KINASE DEPENDANT DE LA CYCLINE
  申请人：WARNER LAMBERT CO

  公开号：WO2001038315A1

  公开（公告）日：2001-05-31

  This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-quinazolines (I) and (II) that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provides useful intermediates generated during the production of the quinazoline compounds.
• 2-Aminoquinazoline inhibitors of cyclin-dependent kinases
  作者：Yadagiri Bathini、Inderjit Singh、Patricia J. Harvey、Paul R. Keller、Rajeshwar Singh、Ronald G. Micetich、David W. Fry、Ellen M. Dobrusin、Peter L. Toogood

  DOI：10.1016/j.bmcl.2005.05.131

  日期：2005.9

  cell cycle arrest and restores a checkpoint that is absent in the majority of tumor cells. Compounds that inhibit Cdk4 selectively are targeted for treating cancer. Appropriate substitution of 2-aminoquinazolines is demonstrated to produce high levels of selectivity for Cdk4 versus closely related serine-threonine kinases.

  抑制细胞周期蛋白依赖性激酶4（Cdk4）会导致细胞周期停滞，并恢复大多数肿瘤细胞中不存在的检查点。选择性抑制Cdk4的化合物可靶向治疗癌症。与紧密相关的丝氨酸-苏氨酸激酶相比，证明2-氨基喹唑啉的适当取代对Cdk4产生高水平的选择性。